Pharmacological enhancement of treatment for amblyopia

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 409-416

  Rashad, Mohammad A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Amblyopia; Carbidopa; Levodopa; Occlusion

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADOLESCENT; ADULT; AMBLYOPIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PLASTICITY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL CORTEX; VOMITING; XEROSTOMIA;

EID: 84859557249     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S29941     Document Type: Article

References (32)

1. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005; 123:437-447.
2. Rahi J, Logan S, Timms C, Russell-Eggitt I, Taylor DSI. Incidence and causes of new visual loss affecting the non amblyopic eye of individuals with unilateral amblyopia in United Kingdom. Invest Ophthalmol Vis Sci. 2000;41:297.
3. Leguire LE, Rogers GL, Bremer DL, McGregor. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Ophthalmol Strabismus. 1993;30:354-360.
4. Yeh KC, August TF, Busch DF, et al. Pharmacokinetics and bioavailability of Sinemet CR. A summary of human studies. Neurology. 1989;39: 25-38.
5. Sinemet (package insert). Manufactured by Merck Co, Inc, Produced by Elobal Napi Pharmaceuticals, Egypt, under license from Merck Co, Inc, Whitehouse Station, NJ; 2005.
6. Gordon N. Segawa's disease: dopa responsive dystonia. Int J Clin Pract. 2008;62:943-946.
7. Procianoy E, Fuchs FD, Procianoy L, Procianoy F. The effect of increasing doses of levodopa on children with strabismic amblyopia. J AAPOS. 1999;3:337-340.
8. Basmak H, Yildirim N, Erdink O, Yurdakul S, Ozdemir G. Effect of levodopa therapy on visual evoked potentials and visual acuity in amblyopia. Ophthalmologica. 1999;213:110-113.
9. Leguire LE, Rogers GL, Bremer DL, Walson PD, Hadjiconstantinou-Neff M. Levodopa and childhood amblyopia. J Pediatr Ophthalmol Strabismus. 1992;29:290-298.
10. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Levodopa carbidopa treatment for amblyopia in older children. J Pediatr Ophthalmol Strabismus. 1995;32:143-151.
11. Mohan K, Dhankar V, Sharma A. Visual acuities after levodopa administration in amblyopia. J Pediatr Opthalmol Strabismus. 2001;38: 62-67.
12. Leguire LE, Rogers G, Walson PD, Bremer DL, McGregor ML. Occlusion and levodopa carbidopa treatment for childhood amblyopia. J AAPOS. 1998;2:257-264.
13. Leguire LE, Komaromy KL, Nairus TM, Rogers GL. Long term follow up of L-dopa treatment in children with amblyopia. J Pediatr Ophthalmol Strabismus. 2002;39:326-330.
14. Dadeya S, Vats P, Malikk PS. Levodopa carbidopa in the treatment of amblyopia. J Pediatr Ophthalmol Strabismus. 2009;46:87-90.
15. Jaeb Center for Health Research. Levodopa for the treatment of residual amblyopia (ATS17). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 6, 2012]. Available from: http://clinicaltrials.gov/ct2/ show/NCT01190813?term=NCT01190813&rank=1. NLM identifier: NCT01190813. Accessed March 2, 2012.
16. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML. Longitudinal study of levodopa/carbidopa for childhood amblyopia. J Pediatr Opthalmol Strabismus. 1993;30:354-360.
17. Gottlob I, Reinecke RD. Visual acuities and scotomas after 3 weeks' levodopa administration in adult amblyopia. Graefes Arch Clin Exp Ophthalmol. 1995;233:407-413.
18. Bhartiya P, Sharma P, Biswas NR, Tandon R, Khokhar SK. Levodopa/ carbidopa with occlusion in older children with amblyopia. J AAPOS. 2002;6:368-372.
19. Wu X, Liu S, Xu H. A preliminary report of the effect of levodopa and carbidopa for childhood amblyopia. Yan Ke Xue Bao. 1998;14:238-241. Chinese.
20. Stewart CE, Stephens DA, Fielder AR. Objective monitored patching regimens for treatment of amblyopia. Randomized trial. Br Med J. 2007;335:707.
21. Multi-ethnic Pediatric Eye Disease Study Group. Prevalence of amblyopia and strabismus in African American and Hispanic children ages 6 to 72 months. Ophthalmology. 2008;115:1229-1236.
22. Scheiman MM, Hertle RW, Beck RW. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005;123: 437-447.
23. Kasamatsu T. Enhancement of neural plasticity by activating the norepinephrine system in the brain-a remedy for amblyopia. Hum Neurobiol. 1982;1:49-54.
24. Phillipson OT, Kilpatrick IC, Jones MW. Dopaminergic innervation of the primary visual cortex in the rat, and some correlations with human cortex. Brain Res Bull. 1987;18:621-633.
25. Awan M, Proudlock FA, Gottlob I. A randomized controlled trial of unilateral strabismic and mixed amblyopia using occlusion dose monitors to record compliance. Invest Ophthalmol Vis Sci. 2005;46: 1435-1439.
26. Attebo K, Mitchell P, Cumming R. Prevalence and causes of amblyopia in adult population. Ophthalmology. 1998;105:154-159.
27. Wali N, Leguire LE, Rogers GL, Bremer DL. CSF interocular interactions in amblyopia. Optom Vis Sci. 1991;68:81-87.
28. Nguyen-Lergos J, Durand J, Simon A. Catecholamine cell types in the human retina. Clin Vis Sci. 1992;7:435-447.
29. Demer JL, Von Noorden GK, Volkow ND. Imaging of cerebral blood flow and metabolism in amblyopia by positron emission tomography. Am J Ophthalmol. 1988;105:337-347.
30. Sireteanu R, Tonhousen N, Muckli L. Cortical site of amblyopic deficit in anisometropic and strabismic subjects investigated with MRI. Invest Ophthalmol Vis Sci. 1998;39 Suppl:S909.
31. Von Noorden GK, Crawford ML. The lateral geniculate nucleus in human strabismic amblyopia. Invest Ophthalmol Vis Sci. 1992;33: 2729-2732.
32. Chua B, Mitchell P. Consequences of amblyopia on education, occupation and long term visual loss. Br J Ophthalmol. 2004;88: 1119-1121.